Amgen is investing $1 billion to establish a second drug substance manufacturing facility in North Carolina. This brings the company’s total planned investment in Holly Springs to more than $1.5 billion, building on its previously announced $550 million commitment.   The $1 billion facility will incorporate cutting-edge technologies. In tandem with the existing facility, these investments will create 370 new jobs in the region.   “This expansion underscores our unwavering focus o...